Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. Issue 4 (22nd January 2020)

• Record Type: Journal Article
• Authors: Marín-López, Alejandro; Barreiro-Piñeiro, Natalia; Utrilla-Trigo, Sergio; Barriales, Diego; Benavente, Javier; Nogales, Aitor; Martínez-Costas, José; Ortego, Javier; Calvo-Pinilla, Eva
• Is Part Of: Vaccine. Volume 38:Issue 4(2020)
• Page Start: 882
• Page End: 889
• Publication Date: 2020-01-22
• Subjects: African horse sickness -- Microspheres -- MVA -- Multiserotype -- Vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.10.087
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Microspheres containing and rMVAs expressing protein NS1 were generated as experimental vaccines for AHSV. Mice primed with MS-NS1 and boosted with MS-NS1 or MVA-NS1 were protected after infection with homologous AHSV. The combination of microspheres and rMVA in the vaccination strategy triggered a specific cytotoxic CD8 + T cell response. Immunization of mice with MS-MVA-NS1 elicited cross-protection against a different AHSV serotype. Abstract: African horse sickness virus (AHSV) is an insect-borne pathogen that causes acute disease in horses and other equids. In an effort to improve the safety of currently available vaccines and to acquire new knowledge about the determinants of AHSV immunogenicity, new generation vaccines are being developed. In this work we have generated and tested a novel immunization approach comprised of nonstructural protein 1 (NS1) of AHSV serotype 4 (AHSV-4) incorporated into avian reovirus muNS protein microspheres (MS-NS1) and/or expressed using recombinant modified vaccinia virus Ankara vector (MVA-NS1). The protection conferred against AHSV by a homologous MS-NS1 or heterologous MS-NS1 and MVA-NS1 prime/boost was evaluated in IFNAR (−/−) mice. Our results indicate that immunization based on MS-NS1 and MVA-NS1 afforded complete protection against the infection with homologous AHSV-4. Moreover, priming with MS-NS1 and boost vaccination with MVA-NS1 (MS-MVA-NS1) triggered NS1 specific cytotoxic CD8 + T cells and prevented AHSV disease in IFNAR (−/−) mice after challenge with heterologous serotype AHSV-9. Cross-protective immune responses are highly important since AHS can be caused by nine different serotypes, which means that a universal polyvalent vaccination would need to induce protective immunity against all serotypes.